echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Angiogenesis: a plasma biomarker that can predict the risk of bevacizumab-induced hypertension

    Angiogenesis: a plasma biomarker that can predict the risk of bevacizumab-induced hypertension

    • Last Update: 2021-06-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Hypertension is a common side effect of bevacizumab and other anti- angiogenic drugs .


    Hypertension is bevacizumab and other anti- vascular generation drugs common side effects vessels

    The study aims to identify plasma proteins related to the function of the vascular system to predict the risk of bevacizumab-induced hypertension.


    Pretreated plasma samples from 398 patients treated with bevacizumab in two clinical trials (CALGB 80303 and 90401) were collected, and the levels of 17 proteins were detected by ELISA.


    398 patients receiving bevacizumab

    The average level of 17 proteins in the plasma of two test subjects

    The average level of 17 proteins in the plasma of two test subjects

    There were no differences in the levels of the five proteins in clinical trials and were included in further analysis.


    Lower levels of Angiopoietin-2 , VEGF-A, and VCAM-1 are associated with an increased risk of grade 3 hypertension.


    The levels of angiopoietin-2, VEGF-A and VCAM-1 in patients with ≥ grade 3 hypertension

    The levels of angiopoietin-2, VEGF-A and VCAM-1 in patients with ≥ grade 3 hypertension

    The multivariate model suggested that Angiopoietin-2 (p=0.


    The reduction in the levels of these three proteins or two of them at the same time indicates that the risk of bevacizumab-induced hypertension is further increased: OR 10.


    Original source:

    Original source:

    Quintanilha Julia CF,Liu Yingmiao,Etheridge Amy S et al.


    org/10.
    1007/s10456-021-09799-1">Plasma levels of angiopoietin-2, VEGF -A, and VCAM-1 as markers of bevacizumab-induced hypertension: CALGB 80303 and 90401 (Alliance)

    in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.